7-methoxy-3,4,5,10-tetrahydro-1H-2,5-methanoazepino[3,4-b]indole-1-carboxylic Acid | 837381-25-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-methoxy-3,4,5,10-tetrahydro-1H-2,5-methanoazepino[3,4-b]indole-1-carboxylic Acid
• 英文别名: 5-methoxy-9,12-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraene-11-carboxylic acid
• CAS: 837381-25-6
• 化学式: C₁₅H₁₆N₂O₃
• 分子量: 272.304
• InChiKey: YRWZXBDQPAUWNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  65.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-methoxy-3,4,5,10-tetrahydro-1H-2,5-methanoazepino[3,4-b]indole-1-carboxylic Acid 、 苏合香醇 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 反应 5.0h， 生成 1-Phenylethyl 5-methoxy-9,12-diazatetracyclo[10.2.1.0^{2,10}.0^{3,8}]pentadeca-2(10),3,5,7-tetraene-11-carboxylate
  参考文献：
  名称：

  Novel tetrahydro-β-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2)

  摘要：

  A structure-activity relationship study was conducted on a series of tetrahydro-beta-carboline-1-carboxylic acid analogs in order to identify the key functionality responsible for activity against the mitogen-activated protein kinase-activated protein kinase 2 enzyme (MK-2). The compounds were further evaluated for their ability to inhibit TNF alpha production in U937 cells and in vivo. These compounds represent a novel structural class of compounds capable of inhibiting MK-2 with remarkable selectivity. (c) 2007 Elsevier Ltd. All rialuts reserved.

  DOI：

  10.1016/j.bmcl.2007.05.070
• 作为产物：
  描述：

  5-methoxy-3-(pyrrolidin-3-yl)indole 、 乙醛酸水合物 在 水 、 乙醚 作用下， 以 甲醇 、 水 为溶剂， 反应 10.0h， 以to give the title compound as a tan solid (105 g, 385 mmol, 91% yield, 9:1 mixture of diastereomers)的产率得到7-methoxy-3,4,5,10-tetrahydro-1H-2,5-methanoazepino[3,4-b]indole-1-carboxylic Acid
  参考文献：
  名称：

  Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors

  摘要：

  本发明提供了新型的桥接β-喹啉衍生物，能够抑制有丝分裂原活化蛋白激酶激活蛋白激酶-2及其类似物，并且包括这些化合物的制药组合物和试剂盒。

  公开号：

  US20050101623A1

文献信息

• METHODS AND COMPOSITIONS FOR TREATING CELLULAR PROLIFERATIVE DISEASES
  申请人：THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY

  公开号：EP1824498A2

  公开（公告）日：2007-08-29
• Methods and compositions for treating cellular proliferative diseases
  申请人：Yaffe B. Michael

  公开号：US20060115453A1

  公开（公告）日：2006-06-01

  The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, screening assays for identifying such compounds, and methods for treating such disorders.
• Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
  申请人：Yaffe Michael B.

  公开号：US20090010927A1

  公开（公告）日：2009-01-08

  The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.
• Methods for Diagnosing and Treating Cancer
  申请人：Yaffee Michael B.

  公开号：US20120252737A1

  公开（公告）日：2012-10-04

  The invention provides methods for decreasing one or more symptoms of cancer in a patient requiring the steps of determining the activation or inactivation of the MK2 signaling pathway and, based on these determinations, administering either a MK2 inhibitor or a combination of a MK2 inhibitor and a chemotherapeutic agent, or a chemotherapeutic agent to the patient. The invention further provides methods for identifying a cancer patient that may selectively benefit from the administration of a chemotherapeutic agent, or the administration of a MK2 inhibitor or the combination of a MK2 inhibitor and a chemotherapeutic agent, requiring the steps of determining the activation or inactivation of the MK2 signaling pathway. The invention additionally provides methods and kits for diagnosing a chemotherapy-sensitive or chemotherapy-resistant cancer in a subject that require the step of (or reagents for) determining the activation or inactivation of the MK2 signaling pathway. The invention also provides methods of treating a cancer patient diagnosed as having a chemotherapy-sensitive or a chemotherapy-resistant cancer.
• Mapkap Kinase-2 as a Specific Target for Blocking Proliferation of P53-Defective Cells
  申请人：Massachusetts Institute of Technology

  公开号：US20140037755A1

  公开（公告）日：2014-02-06

  The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.